Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer

NCT01507428 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2026-04-21

Study results available
· View outcomes & findings →

Summary

This randomized phase II trial studies how well positron emission tomography (PET)/computed tomography (CT)-guided radiation therapy works compared to standard radiation therapy in treating patients with stage III non-small cell lung cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Using imaging procedures, such as PET and CT scans, to guide the radiation therapy, may help doctors deliver higher doses directly to the tumor and cause less damage to healthy tissue.

Conditions

  • Stage III Lung Non-Small Cell Cancer AJCC v7
  • Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  • Stage IIIB Lung Non-Small Cell Cancer AJCC v7

Interventions

RADIATION

Image-Guided Adaptive Radiation Therapy

Undergo individualized adaptive radiotherapy

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Paclitaxel

Given IV

PROCEDURE

Positron Emission Tomography

Undergo FDG PET/CT

PROCEDURE

Positron Emission Tomography

Undergo FMISO PET/CT (Correlative studies)

DRUG

Fludeoxyglucose F-18

Undergo FDG PET/CT

DRUG

18F-Fluoromisonidazole

Undergo FMISO PET/CT (Correlative studies)

DRUG

Carboplatin

Given IV

PROCEDURE

Computed Tomography

Undergo FDG PET/CT

PROCEDURE

Computed Tomography

Undergo FMISO PET/CT (Correlative studies)

RADIATION

External Beam Radiation Therapy

Undergo radiotherapy

Sponsors & Collaborators

  • NRG Oncology

    collaborator OTHER
  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Feng-Ming (Spring) P Kong · NRG Oncology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-22
Primary Completion
2020-08-17
Completion
2022-05-20

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01507428 on ClinicalTrials.gov